Payer environment will impact biopharma prospects in 2017

January 31, 2017 Christoph Graener

An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay, head of Informa Pharma Intelligence Products, shares with Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, his thoughts on how shareholder pressure for genuine patient benefits has implications for the pharma and biotech industries.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Michael Hay – Head, Intelligence Products, Informa Pharma Intelligence

Previous Article
Keryx looks to label expansion to drive Auryxia

Keryx plans to expand Aurexia’s label to treat iron deficiency in pre-dialysis patients while searching for...

Next Article
J&J poised to establish no-strings-attached JLABS outside America

As J&J announced the establishment of its eighth JLABS facility, Melinda Richter, head of J&J Innovation, J...